title: Protection from procedural myocardial injury by omega-3 polyunsaturated fatty acids (PUFAs): is related with lower levels of creatine kinase-MB (CK-MB) and troponin I?
abstract: OBJECTIVE
  This study sought to investigate the effect of omega-3 polyunsaturated fatty acids (PUFAs) on cardiac biomarkers, CK-MB, and troponin I in patients undergoing PCI.
  
  
  BACKGROUND
  Restenosis remains as a major long-term complication following percutaneous coronary intervention (PCI). It appears that there is strong relationship between post-PCI creatine kinase-MB (CK-MB) and troponin I elevation and cardiovascular events after PCI.
  
  
  METHODS
  In this randomized clinical trial, a total of 90 patients planned to undergo PCI were randomly assigned into two groups: Group A-receiving omega-3 PUFAs (3 g, 12 h before PCI) plus standard treatment (n = 43) and Group B-control group, receiving only standard therapy (n = 47). Standard treatment included aspirin 325 mg and clopidogrel 600 mg loading dose. The plasma CK-MB level was measured before the procedure (baseline), at 8 and 24 h after PCI. The plasma troponin I was measured at baseline and 24 h after PCI.
  
  
  RESULTS
  In comparison with control, omega-3 PUFAs could significantly reduce the level of CK-MB in 8 (P = 0.001) and 24 h (P = 0.012) after its prescription in the omega-3 PUFAs group. Omega-3 PUFAs could not significantly decrease troponin I.
  
  
  CONCLUSIONS
  Our results revealed that omega-3 PUFAs can be considered as a safe adjunctive medication to the standard regimen before PCI for the aim of decreasing cardiovascular event after PCI.
authors.affiliation: Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Farzaneh
authors.initials: F
authors.lastname: Foroughinia
authors.forename: Jamshid
authors.initials: J
authors.lastname: Salamzadeh
authors.forename: Mohammad H
authors.initials: MH
authors.lastname: Namazi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D052279:Creatine Kinase, MB Form / Q000097:blood*; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects*; D011446:Prospective Studies; D016037:Single-Blind Method; D019210:Troponin I / Q000097:blood*
chemical_list: D015525:Fatty Acids, Omega-3; D019210:Troponin I; D052279:Creatine Kinase, MB Form
keywords: Cardiac biomarkers; Creatine kinase-MB; Omega-3 polyunsaturated fatty acids; Percutaneous coronary intervention; Procedural myocardial injury; Troponin I